Shield Therapeutics plc (LSE:STX) — Market Cap & Net Worth
Market Cap & Net Worth: Shield Therapeutics plc (STX)
Shield Therapeutics plc (LSE:STX) has a market capitalization of $519.78K (GBX4.27 Billion) as of August 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30902 globally and #917 in its home market, demonstrating a -31.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shield Therapeutics plc's stock price GBX4.00 by its total outstanding shares 1067997016 (1.07 Billion). See how much does Shield Therapeutics plc reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Shield Therapeutics plc Market Cap History: 2016 to 2026
Shield Therapeutics plc's market capitalization history from 2016 to 2026. Data shows change from $21.22 Million to $519.78K (-29.23% CAGR).
Index Memberships
Shield Therapeutics plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$927.28 Million | 0.06% | #224 of 722 |
Weight: Shield Therapeutics plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Shield Therapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shield Therapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Shield Therapeutics plc's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $21.22 Million | $304.00K | -$15.02 Million | 69.81x | N/A |
| 2017 | $13.80 Million | $637.00K | -$19.59 Million | 21.66x | N/A |
| 2018 | $3.74 Million | $11.88 Million | -$1.79 Million | 0.31x | N/A |
| 2019 | $21.96 Million | $719.00K | -$8.80 Million | 30.54x | N/A |
| 2020 | $7.79 Million | $10.39 Million | -$2.63 Million | 0.75x | N/A |
| 2021 | $5.83 Million | $1.52 Million | -$19.34 Million | 3.84x | N/A |
| 2022 | $916.11K | $5.50 Million | -$40.44 Million | 0.17x | N/A |
| 2023 | $870.63K | $13.09 Million | -$33.29 Million | 0.07x | N/A |
| 2024 | $350.85K | $25.18 Million | -$21.27 Million | 0.01x | N/A |
Competitor Companies of STX by Market Capitalization
Companies near Shield Therapeutics plc in the global market cap rankings as of August 7, 2026.
Key companies related to Shield Therapeutics plc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #541 globally with a market cap of $49.98 Billion USD ( CN¥341.53 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #551 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #541 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.98 Billion | CN¥53.54 |
| #551 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $44.04 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.20 |
Shield Therapeutics plc Historical Marketcap From 2016 to 2026
Between 2016 and today, Shield Therapeutics plc's market cap moved from $21.22 Million to $ 519.78K, with a yearly change of -29.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX519.78K | -59.39% |
| 2025 | GBX1.28 Million | +264.81% |
| 2024 | GBX350.85K | -59.70% |
| 2023 | GBX870.63K | -4.96% |
| 2022 | GBX916.11K | -84.29% |
| 2021 | GBX5.83 Million | -25.13% |
| 2020 | GBX7.79 Million | -64.53% |
| 2019 | GBX21.96 Million | +486.89% |
| 2018 | GBX3.74 Million | -72.89% |
| 2017 | GBX13.80 Million | -34.97% |
| 2016 | GBX21.22 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Shield Therapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $519.78K USD |
| MoneyControl | $519.78K USD |
| MarketWatch | $519.78K USD |
| marketcap.company | $519.78K USD |
| Reuters | $519.78K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the… Read more